Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
HZNP Horizon Therapeutics Public Limited Company weekly Stock Chart
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Healthcare | Drug Manufacturers - General | Ireland
statements
Index- P/E19.13 EPS (ttm)3.66 Insider Own0.60% Shs Outstand220.71M Perf Week-1.17%
Market Cap15.67B Forward P/E14.23 EPS next Y4.92 Insider Trans-24.02% Shs Float218.00M Perf Month-9.54%
Income792.00M PEG0.64 EPS next Q1.03 Inst Own90.10% Short Float2.35% Perf Quarter-4.98%
Sales1.82B P/S8.61 EPS this Y736.30% Inst Trans6.33% Short Ratio2.36 Perf Half Y42.67%
Book/sh17.88 P/B3.92 EPS next Y36.51% ROA16.60% Target Price100.67 Perf Year125.97%
Cash/sh7.71 P/C9.08 EPS next 5Y30.10% ROE30.10% 52W Range23.81 - 86.67 Perf YTD93.51%
Dividend- P/FCF79.37 EPS past 5Y23.90% ROI18.70% 52W High-20.32% Beta1.18
Dividend %- Quick Ratio3.40 Sales past 5Y34.40% Gross Margin74.40% 52W Low190.05% ATR3.22
Employees1275 Current Ratio3.50 Sales Q/Q89.70% Oper. Margin15.00% RSI (14)38.39 Volatility3.07% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q1506.00% Profit Margin43.50% Rel Volume1.05 Prev Close70.05
ShortableYes LT Debt/Eq0.26 EarningsNov 02 BMO Payout0.00% Avg Volume2.18M Price69.06
Recom1.60 SMA20-6.67% SMA50-10.29% SMA20024.20% Volume987,085 Change-1.41%
Sep-09-20Initiated JP Morgan Overweight $110
Aug-27-20Initiated Citigroup Buy $112
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Nov-23-20 08:00AM  
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
PR Newswire
08:00AM  
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Business Wire
Nov-19-20 01:03PM  
Top Healthcare Stocks for December 2020
Investopedia
Nov-18-20 10:11AM  
Investing Strategies: Horizon Therapeutics CEO, Chegg CFO, O'Neil Investment Strategist Share Insights
Investor's Business Daily
Nov-17-20 09:15AM  
National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
Business Wire
Nov-16-20 10:54AM  
First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
Business Wire
Nov-13-20 10:40AM  
Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
Investor's Business Daily
10:31AM  
Atara Biotherapeutics Moves With Rising Relative Price Strength
Investor's Business Daily
08:30AM  
New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
Business Wire
08:00AM  
Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
Business Wire
Nov-12-20 08:00AM  
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Business Wire
Nov-03-20 12:50AM  
Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans
Investor's Business Daily Video
Nov-02-20 04:15PM  
Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls
Investor's Business Daily
02:00PM  
Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Business Wire
08:12AM  
Horizon Therapeutics: Q3 Earnings Insights
Benzinga
07:00AM  
Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
Business Wire
06:58AM  
Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Business Wire
Oct-30-20 09:15AM  
Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
Business Wire
08:00AM  
New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
Business Wire
Oct-29-20 03:17PM  
AGC Biologics and Horizon Therapeutics plc Expand Partnership
PR Newswire
03:00PM  
AGC Biologics and Horizon Therapeutics plc Expand Partnership
PR Newswire
02:25PM  
Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily
08:00AM  
Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Business Wire
Oct-26-20 10:04PM  
Were Hedge Funds Right About Crowding Into Horizon Therapeutics (HZNP)?
Insider Monkey
08:00AM  
Horizon Therapeutics plc Named One of the Most Innovative Companies by Crains Chicago Business
Business Wire
07:29AM  
Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Is An Interesting Stock
Simply Wall St.
Oct-23-20 08:00AM  
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Business Wire
Oct-22-20 10:00AM  
New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
Business Wire
Oct-20-20 08:00AM  
Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
Business Wire -5.29%
Oct-16-20 11:05AM  
Dow Jones, Nasdaq Reheat Rally As Stock Market Today Ushers New Breakouts
Investor's Business Daily
08:30AM  
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
Business Wire
Oct-14-20 08:00AM  
TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
Business Wire
Oct-09-20 06:14PM  
Cannabis Use Is on the Rise. Where to Invest Now.
Barrons.com
Oct-08-20 08:15AM  
New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
Business Wire
08:00AM  
Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
Business Wire
Oct-07-20 08:00AM  
Horizon Therapeutics plc Named One of San Francisco Bay Areas Best and Brightest Companies to Work For
Business Wire
Oct-06-20 04:22PM  
Dow Jones Sinks Over 375 Points After Trump Chills Stimulus Talks
Investor's Business Daily
Oct-05-20 07:45PM  
The 21-Day Exponential Moving Average: Why This Is Your New Edge
Investor's Business Daily
08:00AM  
Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
Business Wire
Oct-01-20 04:00PM  
Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
Business Wire
Sep-29-20 08:00AM  
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Shares Could Be 35% Below Their Intrinsic Value Estimate
Simply Wall St.
Sep-23-20 04:14PM  
Horizon Therapeutics Stock Hits Record High As Sales Of Key Drug Top Views
Investor's Business Daily
Sep-16-20 04:33PM  
Stocks Today End Mixed; Two Of These Four Breakouts Undercut Their Buy Points
Investor's Business Daily
12:19PM  
Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating
Investor's Business Daily
08:00AM  
MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Business Wire
Sep-15-20 11:37AM  
Horizon Therapeutics Is A Buy
Investor's Business Daily Video
10:48AM  
Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
Investor's Business Daily
Sep-14-20 05:34PM  
Dow Jones Futures: Stock Market Rally Gets A Win As Tesla, Nvidia Jump, Apple In Buy Zone; Tesla Rival Nikola Dives On SEC Probe
Investor's Business Daily +8.59%
Sep-10-20 12:11PM  
Sangamo Therapeutics Getting Closer To Key Technical Benchmark
Investor's Business Daily
Sep-08-20 10:24AM  
Hedge Funds Never Been This Bullish On Horizon Therapeutics (HZNP)
Insider Monkey
Sep-03-20 10:23AM  
Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock Is Going Strong: Is the Market Following Fundamentals?
Simply Wall St.
Sep-02-20 09:00AM  
Horizon Therapeutics plc Named to the 2020 PEOPLE "50 Companies That Care" List
Business Wire
Sep-01-20 08:00AM  
Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Business Wire
Aug-28-20 04:29PM  
Horizon Therapeutics, IBD Stock Of The Day, Rides Rare-Disease Drug To Buy Points
Investor's Business Daily
11:03AM  
Horizon Therapeutics Sets Up
Investor's Business Daily Video
Aug-27-20 09:56AM  
Dow Jones Today, Stocks Mixed On Powell's 'Robust Update;' NetApp Stirs Database Stocks, Abbott Gets FDA Covid Nod
Investor's Business Daily
Aug-26-20 01:33PM  
Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating
Investor's Business Daily
01:11PM  
Stocks To Watch: Insmed Sees RS Rating Rise To 83
Investor's Business Daily
12:23PM  
Stock Upgrades: Amgen Shows Rising Relative Strength
Investor's Business Daily
Aug-11-20 05:00PM  
Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Ordinary Shares
Business Wire -5.50%
Aug-10-20 09:00AM  
Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crains Chicago Business
Business Wire
Aug-09-20 09:10AM  
3 Monster Growth Stocks That Can Rip Higher
TipRanks
Aug-08-20 10:58AM  
Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Business Is Trailing The Market But Its Shares Aren't
Simply Wall St.
Aug-06-20 11:20PM  
Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
Business Wire -5.45%
09:00AM  
Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune
Business Wire
Aug-05-20 04:01PM  
Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
Business Wire +23.61%
12:26PM  
Why Horizon Therapeutics Stock Is Up Today
Motley Fool
07:46AM  
Recap: Horizon Therapeutics Q2 Earnings
Benzinga
07:00AM  
Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $650 Million; Increases FullYear 2020 Net Sales and Adjusted EBITDA Guidance
Business Wire
Jul-31-20 07:00AM  
New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
Business Wire
Jul-24-20 02:25PM  
Horizon Therapeutics' (NASDAQ:HZNP) Wonderful 383% Share Price Increase Shows How Capitalism Can Build Wealth
Simply Wall St.
Jul-22-20 08:00AM  
Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance Response Rates for People Living with Uncontrolled Gout
Business Wire
Jul-13-20 08:30AM  
Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020
Business Wire
Jul-09-20 08:30AM  
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
Business Wire
08:00AM  
HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout
PR Newswire
Jul-08-20 10:00AM  
Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market
Investor's Business Daily
Jul-07-20 04:49PM  
Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP) ?
Insider Monkey
Jul-01-20 09:00AM  
New Initiative Encourages the Graves Disease Community to FOCUS on Eye Health
Business Wire
Jun-23-20 11:38AM  
These 3 Growth Stocks Could Hold Value
GuruFocus.com
Jun-03-20 08:05AM  
Horizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
Business Wire
08:00AM  
Data Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
Business Wire
May-30-20 01:06PM  
Is Horizon Therapeutics (HZNP) A Good Stock To Buy?
Insider Monkey
May-27-20 03:36PM  
Edited Transcript of HZNP earnings conference call or presentation 6-May-20 12:00pm GMT
Thomson Reuters StreetEvents
May-21-20 09:15AM  
Horizon Therapeutics Named Number One Best Workplace in Chicago
Business Wire
08:00AM  
Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
Business Wire
May-19-20 08:00AM  
Horizon Therapeutics to Participate in Upcoming Investor Conferences
Business Wire
May-14-20 09:00AM  
New Data on the Pharmacokinetic Profile of TEPEZZA (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
Business Wire
May-11-20 12:00PM  
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
Business Wire
May-06-20 12:39PM  
Why Horizon Therapeutics Is Soaring Today
Motley Fool +13.96%
10:43AM  
Horizon Therapeutics Breaks Out
Investor's Business Daily Video
07:00AM  
Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
Business Wire
Apr-27-20 08:10AM  
Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
Business Wire
Apr-15-20 08:00AM  
Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
Business Wire
Apr-09-20 09:00AM  
Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
Business Wire
Apr-02-20 08:00AM  
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Business Wire +5.48%
Mar-31-20 12:00PM  
TEPEZZA (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Business Wire
Mar-26-20 04:15PM  
Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Business Wire
Mar-22-20 10:13PM  
Should You Buy Horizon Pharma Public Limited Company (HZNP)?
Insider Monkey
Mar-18-20 08:01AM  
Should You Worry About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Salary Level?
Simply Wall St. -6.94%
Mar-17-20 02:04PM  
Top Pharmaceutical Stocks for Q2 2020
Investopedia
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McHugh Miles WSr VP & Princ. Acctg OfficerNov 12Sale75.4812,124915,12021,597Nov 13 07:27 PM
Camardo Daniel A.EVP and President, U.S.Nov 06Sale76.763,500268,66330,829Nov 06 06:00 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 05Sale78.9377,5006,117,259100,709Nov 06 06:00 PM
Kent JeffSee remarksNov 05Sale78.9447,9443,784,66351,049Nov 06 06:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerOct 21Option Exercise7.6113,00098,93028,015Oct 21 05:06 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffSep 17Option Exercise14.0521,351299,98257,373Sep 18 05:00 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffSep 16Sale78.888,919703,53136,022Sep 18 05:00 PM
Beeler Brian KEVP, General CounselSep 04Option Exercise14.9128,143419,66664,028Sep 08 04:51 PM
Hoelscher Paul W.EVP, CFOAug 24Sale75.7629,5762,240,702102,925Aug 25 05:16 PM
Walbert Timothy PChairman, President and CEOAug 06Sale72.54110,0007,979,414733,792Aug 07 05:42 PM
GREY MICHAEL GDirectorAug 05Option Exercise3.951,7556,9321,755Aug 07 05:40 PM
GREY MICHAEL GDirectorAug 05Sale73.351,755128,7290Aug 07 05:40 PM
Karnani VikramEVP & President, InternationalAug 03Option Exercise13.1536,772483,63678,941Aug 05 01:24 PM
SANTINI GINODirectorAug 03Option Exercise2.8835,795103,26235,795Aug 04 04:56 PM
GREY MICHAEL GDirectorJul 22Option Exercise3.951,7556,9321,755Jul 22 05:33 PM
GREY MICHAEL GDirectorJul 22Sale60.001,755105,3000Jul 22 05:33 PM
Kent JeffSee remarksJul 07Option Exercise5.6838,000215,98098,993Jul 07 06:57 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 07Option Exercise13.1735,076461,918178,209Jul 07 06:50 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJul 06Sale57.509,100523,250278,797Jul 07 06:49 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 01Sale54.6423,1581,265,441143,133Jul 02 04:46 PM
GREY MICHAEL GDirectorJun 25Option Exercise3.951,7556,9321,755Jun 26 05:00 PM
GREY MICHAEL GDirectorJun 25Sale55.001,75596,5250Jun 26 05:00 PM
Kent JeffSee remarksJun 10Sale48.052,785133,81960,993Jun 12 06:00 PM
Kent JeffSee remarksJun 01Sale49.9457,2152,857,17960,994Jun 02 06:18 PM
Karnani VikramEVP, Chief Commercial OfficerJun 01Sale50.232,369118,99542,169Jun 02 06:17 PM
Beeler Brian KEVP, General CounselJun 01Sale50.232,370119,04535,885Jun 02 06:16 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOMay 26Sale49.8521,9181,092,61234,834May 27 05:00 PM
GREY MICHAEL GDirectorMay 22Option Exercise7.8410,53082,55510,530May 26 05:00 PM
GREY MICHAEL GDirectorMay 22Sale48.7710,530513,5050May 26 05:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Option Exercise4.9633,479166,05647,445May 12 04:12 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Sale45.0033,4791,506,55513,966May 12 04:12 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 11Sale44.2249,1142,171,58530,816May 12 04:11 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 08Sale43.5145,3661,973,71179,930May 12 04:11 PM
DesJardin Michael A.EVP, Technical OperationsMay 07Option Exercise14.9323,159345,76464,359May 07 04:29 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Option Exercise14.0559,794840,10695,183May 07 04:31 PM
Beeler Brian KEVP, General CounselMay 06Sale40.8048,0001,958,51537,206May 07 04:32 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Sale41.1959,7942,462,91535,389May 07 04:31 PM
DesJardin Michael A.EVP, Technical OperationsMay 06Sale41.5917,959747,00441,200May 07 04:29 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 06Sale41.193,545146,019129,095May 07 04:30 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 05Sale37.005,007185,259132,640May 07 04:30 PM
DesJardin Michael A.EVP, Technical OperationsMay 05Sale38.008,980341,24059,159May 07 04:29 PM
Hoelscher Paul W.EVP, CFOMay 05Sale38.00104,9943,989,772132,501May 07 04:27 PM
Beeler Brian KEVP, General CounselApr 29Sale35.0215,880556,11885,206Apr 30 05:50 PM
Karnani VikramEVP, Chief Commercial OfficerApr 29Sale35.0015,683548,90543,489Apr 30 05:49 PM
Karnani VikramEVP, Chief Commercial OfficerApr 28Sale35.0130,0631,052,50659,172Apr 30 05:49 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffApr 20Sale34.1319,886678,68535,389Apr 21 05:00 PM
Beeler Brian KEVP, General CounselApr 16Sale32.519,000292,615101,086Apr 17 04:23 PM
Beeler Brian KEVP, General CounselApr 07Sale32.502979,653110,086Apr 08 04:46 PM
Beeler Brian KEVP, General CounselApr 06Sale32.502,37077,025110,383Apr 08 04:46 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Option Exercise12.942,10627,252168,397Mar 31 05:01 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Sale28.182,10659,347166,291Mar 31 05:01 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 11Option Exercise12.945,28768,41413,966Mar 13 04:15 PM
McHugh Miles WSr VP & Princ. Acctg OfficerFeb 27Sale34.341,00034,3420Feb 28 05:00 PM
Walbert Timothy PChairman, President and CEOFeb 21Sale35.2393,8643,306,829847,743Feb 21 08:07 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,086011,818Feb 04 04:14 PM
Kent JeffSee remarksJan 07Sale36.503,545129,393111,667Jan 07 06:30 PM
Karnani VikramEVP, Chief Commercial OfficerJan 06Sale35.629,297331,15978,146Jan 07 06:23 PM
Walbert Timothy PChairman, President and CEOJan 06Sale35.5784,8863,019,395903,309Jan 07 06:18 PM
Beeler Brian KEVP, General CounselDec 18Sale35.006,716235,06077,917Dec 20 04:46 PM
Beeler Brian KEVP, General CounselNov 25Sale32.519,969324,09384,633Nov 27 04:18 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.